StreetInsider.com  4 hrs ago  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+%28HEB%29+Reports+Pubication+of+Encouraging+Data+on+Alferon+N+as+H5N1+Blocker/9849981.html for the full story.
Clusterstock  Sep 8  Comment 
A possible Ebola treatment is making the stock of yet another company go nuts. Shares of Hemispherx Biopharma, a small biotech company with a market cap of just $50 million, were up as much as 26% in pre-market trade on Monday after the company...
StreetInsider.com  Sep 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+%28HEB%29+and+USAMRIID+Agree+to+Collaborate+in+Studying+Alferon+and+Ampligen+Against+the+Ebola+Virus/9812659.html for the full story.
StreetInsider.com  Aug 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+%28HEB%29+Says+Drugs+Ranked+High+in+MERSSARS+Testing%3B+Co+Met+with+Gov.+to+Discuss+Ebola/9716016.html for the full story.
StreetInsider.com  Jul 14  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+%28HEB%29+Announced+Strategic+Alliance+With+Bioclones/9657209.html for the full story.
StreetInsider.com  Jun 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+%28HEB%29+Says+Study+Confirms+Activity+of+Alferon+N+Against+MERS/9549355.html for the full story.
Benzinga  May 27  Comment 
Hemispherx Biopharma, Inc. (NYSE: HEB) (the "Company" or "Hemispherx"), announced that on May 13, 2014, the United States Patent Office issued U.S. Patent 8,722,874 titled "Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure...
Benzinga  May 14  Comment 
Hemispherx Biopharma, Inc. (NYSE: HEB) (the "Company" or "Hemispherx"), announced that it has entered into a formal collaborative research agreement to test Alferon N Injection®, the only multi-species, natural alpha interferon commercially...
StreetInsider.com  May 5  Comment 
Broadscoft, Inc. (NASDAQ: BSFT) 15.4% LOWER; reported Q1 EPS of $0.07, $0.03 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $43.9 million versus the consensus estimate of $44.84 million. Broadscoft, Inc. sees Q2...
StreetInsider.com  May 5  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+%28HEB%29+Reports+Effectiveness+of+Alferon+N+Against+MERS/9443051.html for the full story.

You may also be interested in articles related to Hemispherx BioPharma (HEB):

Hemispherx Biopharma, Inc (HEB) is a medical research company focusing on a new group of medicinal products knows as nucleic acid compounds.

HEB’s main focus is the treatment of Influenza and various Flu Strains through Ampligen®. However, Ampligen® may also serve as a treatment for Chronic Fatigue Syndrome (CFS). Ampligen®, the company’s main candidate is expected to receive FDA approval in the coming weeks. Other projects include Alferon N® which works as an indicator for recurring herpes.

Lack of diversified products, alternative remedies, failure to be approved by the FDA, and possible lawsuits from patients after approval, make this a very high risk company. But if approval by the FDA and wide acceptance of doctors world wide is accomplished many investors expect the stock value to rise too significantly too pass this investment by.

It is a New York City based corporation trading on AMEX.


http://www.google.com/finance?q=heb , http://www.hemispherx.net , http://www.pr-inside.com/post-approval-hemispherx-ampligen-pps-r1293461.htm ,

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki